Scotland

Vumerity Added to NHS of Scotland for People With Active RMMS

Note: An earlier version of this story stated the Scottish Medicines Consortium approved Vumerity for RRMS patients in that country. The consortium decides to add a medicine to Scotlandā€™s National Health Service; the MHRA approves treatments for England, Scotland, and Wales. The Scottish Medicines Consortium has approved adding the…

Zeposia Tablets Approved in Scotland to Treat Active RRMS

The Scottish Medicines Consortium (SMC) has approvedĀ Zeposia (ozanimod)Ā for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is sold as a tablet, to be taken by mouth once daily. The SMC has recommended that Zeposia be prescribed for people with RRMS who experience relapses or have evidence of…

Mayzent Approved for Active Secondary Progressive MS in Scotland

The Scottish Medicines Consortium (SMC) has approved Mayzent (siponimod) for the treatment of active secondary progressive multiple sclerosis (SPMS) in Scotland. Mayzent, developed by Novartis, is a tablet taken once daily to counter a person’s disability progression. SPMS gradually develops from relapsing-remitting MS, and is…

Fampyra, Aid for Walking, Favored for Inclusion in NHS Scotland

After being rejected twice in the last four years, Fampyra (fampridine; marketed as Ampyra in the U.S.) is now being recommended by the Scottish Medicines ConsortiumĀ (SMC) for use in the country’sĀ National Health System (NHS) to treat walking disabilities in adults withĀ multiple sclerosis (MS). Scotland…

Scottish Medicines Consortium Approves Ocrevus for Treating PPMS

Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS). The Scottish Medicines Consortium (SMC) has advised that OcrevusĀ can be prescribed by the National Health Service (NHS) forĀ people with PPMS who have had symptoms for less than 15…